Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
Montreal, Quebec--(Newsfile Corp. - August 31, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the expansion of its radiopharmaceutical development program to evaluate alpha-emitting and beta-emitting radioisotopes. This expansion is to broaden the capabi
Biotechnology, Pharmaceuticals, Health
2026-08-31 3:15 AM EDT | Defence Therapeutics Inc.
Sharp Therapeutics Corp. Reports First Half 2026 Results and Development Update
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 28, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its unaudited condensed interim consolidated financial statements for the six-month period ended June 30, 2026, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stated. Scott Sneddon, Sharp's Chief Executive Off
2026-08-28 5:01 PM EDT | Sharp Therapeutics Corp.
Theralase(R) Releases Q2 2026 Financial Statements
Toronto, Ontario--(Newsfile Corp. - August 28, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, has released the Company's unaudited interim consolidated financial statements for the six-month period ended Jun
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-28 4:36 PM EDT | Theralase Technologies Inc.
MustGrow Announces Second Quarter 2026 Financial Results
Investor Webcast: Monday, August 31st at 4:00pm ET / 1:00pm PT Register/View Here: https://us02web.zoom.us/webinar/register/1317861230560/WN_oKTSGbCQR1KjX5MnyGC3kw#/registration Please join/register at least 5 minutes prior to the call. Email questions to info@mustgrow.ca before 2:00pm ET, which will be addressed during the Q&A portion of
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2026-08-27 5:01 PM EDT | MustGrow Biologics Corp.
Moss Genomics Inc. Provides Default Status Disclosure and Update on Continuous Disclosure Review
Vancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - As a result of a review by the British Columbia Securities Commission (the "BCSC"), Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company") is issuing the following news release to clarify its disclosure. The Company advises that, on July 14, 2026, it was added to the BCSC's Issuers in Default list under Canadian Securities Administrators Notice 51-322 - Reporting Issuer Defaults. The default arise
2026-08-25 9:22 AM EDT | Moss Genomics Inc.
BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy
Vancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies focused on the early detection of lung cancer through metabolomics, is pleased to announce crucial updates reinforcing the clinical translation of its liquid biopsy technology platform for early non-small cell lung cancer (NSCLC) screening and risk stratification with the public
Technology, Biotechnology, Healthcare and Hospitals
2026-08-25 8:30 AM EDT | BioMark Diagnostics, Inc.
TempraMed Signs Definitive Five-Year Saudi Arabia Distribution Agreement for Private-Label VIVI Cap
Highlights Five-year definitive agreement with approximately US$3.8 million in potential minimum purchase commitments, beginning with a firm 10,000-unit initial purchase order. Agreement covers a private-label version of VIVI Cap™ intended for retail commercialization through the physical pharmacy network of Nahdi Medical Company, Saudi Arabia's largest pharmacy chain. TempraMed believes t
Technology, Biotechnology, Pharmaceuticals, Health
2026-08-25 7:00 AM EDT | TempraMed Technologies Ltd.
Theralase(R) Closes C$3.6 Million Brokered Financing
Toronto, Ontario--(Newsfile Corp. - August 24, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has closed its previously announced brokered private placement offering ("Offering")
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-24 5:01 PM EDT | Theralase Technologies Inc.
NorthPalm Commits Entire Cybeats Position to a 12-Month Lock-Up; 60 Million Shares Representing Approximately 30% of Cybeats
Toronto, Ontario--(Newsfile Corp. - August 24, 2026) - NorthPalm Capital Corp. (CSE: NP) ("NorthPalm" or the "Company"), is pleased to announce that it has committed to a 12-month lock-up of its entire remaining position of 60,000,000 common shares of Cybeats Technologies Corp. (CSE: CYBT) ("Cybeats"), representing approximately 30% of Cybeats' outstanding shares. NorthPalm remains the largest institutional shareholder of Cybeats and is committed to maintaining a signif
Biotechnology, Healthcare and Hospitals, Health
2026-08-24 9:39 AM EDT | NorthPalm Capital Corp.
MustGrow Receives First Milestone Payment from Bayer AG
Saskatoon, Saskatchewan--(Newsfile Corp. - August 21, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) ("MustGrow") is pleased to
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2026-08-21 7:00 AM EDT | MustGrow Biologics Corp.
Noveris Health Sciences Announces Proposed Private Placement of Convertible Debentures for up to $500,000
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") is pleased to announce its intention to complete a non-brokered private placement of convertible debentures of the Company (the "Debentures") in an aggregate principal amount of up to $500,000, issuable in increments of $1,000 principal amount, for aggregate gross proceeds of up to $500,000 (the "Offering
2026-08-20 6:14 PM EDT | Noveris Health Sciences Inc.
iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks
Woburn, Massachusetts--(Newsfile Corp. - August 20, 2026) - iSpecimen, (NASDAQ: ISPC) a provider of human biospecimens, recently completed an international cancer research project involving hundreds of cancer blood specimens, with the samples shipped within three weeks of receiving the purchase order. The project involved the coordination of large-scale biospecimen sourcing and fulfillment on an accelerated timeline. Through its network of healthcare and research partners, iSpecimen coo
2026-08-20 4:05 PM EDT | iSpecimen Inc.
Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA
Calgary, Alberta--(Newsfile Corp. - August 20, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is plea
Biotechnology, Pharmaceuticals, Health
2026-08-20 9:44 AM EDT | Hemostemix Inc.
Maxwell Biosciences' Spinout SHU.ai Announces Closing of $1M Financing Round
Austin, Texas--(Newsfile Corp. - August 20, 2026) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired small molecules called Claromers®, December 5, 2025 incorporated its first spinout SHU.ai and June 27, 2026 announced the closing of SHU's $1 million Seed round. The round was oversubscribed and fully funded by private angel investors and led by Keiretsu Forum, "The World's Largest Angel Investor Network." The funds will support accelera
Biotechnology, Pharmaceuticals
2026-08-20 9:00 AM EDT | Maxwell Biosciences, Inc.
TempraMed Announces Extension of Maccabi Healthcare Services Agreement
Toronto, Ontario--(Newsfile Corp. - August 20, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator focused on temperature-sensitive medication protection, is pleased to announce that Maccabi Healthcare Services ("Maccabi"), Israel's second-largest health maintenance organization ("HMO"), has exercised its option to extend its agreement with TempraMed for an additional year u
Technology, Biotechnology, Pharmaceuticals, Health
2026-08-20 7:00 AM EDT | TempraMed Technologies Ltd.
Marvel Biosciences Expands Private Placement to Quebec
Calgary, Alberta--(Newsfile Corp. - August 19, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announces that it is expanding its previously announced private placement (see July 16, 2026 press release) to investors resident in the Province of Quebec. There is an amended and restated offering document related to this Offering dated August 19, 2026 that can be accessed under the Company's profile at www.sedarplus.ca and on the Compa
2026-08-19 1:06 PM EDT | Marvel Biosciences Corp.
Illumisoft Appoints Ehsan Agahi as CEO, Commences Trading on OTCQB Venture Market, Announces Shares for Debt Settlement
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - Illumisoft Lighting Corp. (TSXV: UVC) (OTCQB: FUVCF) ("Illumisoft" or the "Company") today announced that Ehsan Agahi, currently Executive Chairman of the Company, has been appointed Chief Executive Officer, effective August 19, 2026. Mr. Agahi will continue to serve as Chairman of the Board. As Executive Chairman since the completion of the Company's qualifying transaction, Mr. Agahi has been closely involved in Illumiso
Technology, Biotechnology, Healthcare and Hospitals, Household / Consumer / Cosmetics
2026-08-19 7:18 AM EDT | Illumisoft Lighting Corp.
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies. Under the agreement, Kiora will receive a $1 million upfront payment and is eligible to receive development and regul
Biotechnology, Pharmaceuticals
2026-08-19 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Noveris Health Sciences Receives USPTO Notice of Allowance, and Signs Work Order with API
Vancouver, British Columbia--(Newsfile Corp. - August 18, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) ("Noveris" or the "Company") is pleased to announce that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for the Company's U.S. Patent Application No. 18/443,025, titled "Aza-Substituted Psilocin Analogs and Methods of Synthesizing the Same." The Notice of Allowance confirms that all
2026-08-18 5:05 PM EDT | Noveris Health Sciences Inc.
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or
Biotechnology, Pharmaceuticals
2026-08-18 8:00 AM EDT | PharmaTher Holdings Ltd.